Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

LaNova Medicines Initiates First Phase III Clinical Trial for LM-302 in China

  • 2024-04-11

  • Share:

SHANGHAI, April 11th, 2024 – LaNova Medicines Ltd. announced the initiation of its first Phase III clinical trial for LM-302 (anti-Claudin 18.2 ADC) in China. This marks the first antibody-drug conjugate candidate in LaNova's pipeline to enter the pivotal clinical study.

The clinical study (CTR20240955) is a randomized, open-label, multi-center, positive-controlled Phase III trial primarily assessing the efficacy and safety of LM-302 in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma who are CLDN18.2 positive.